Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Financing Activities (2023 - 2025)

Corvus Pharmaceuticals (CRVS) has 3 years of Cash from Financing Activities data on record, last reported at $360000.0 in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 620.0% year-over-year to $360000.0; the TTM value through Sep 2025 reached $55.0 million, up 596.33%, while the annual FY2024 figure was $49.0 million, 524.16% up from the prior year.
  • Cash from Financing Activities reached $360000.0 in Q3 2025 per CRVS's latest filing, down from $35.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $35.8 million in Q2 2025 and bottomed at $4000.0 in Q1 2023.
  • Average Cash from Financing Activities over 3 years is $7.9 million, with a median of $347500.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: crashed 85.07% in 2024, then soared 620.0% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $335000.0 in 2023, then skyrocketed by 5454.63% to $18.6 million in 2024, then tumbled by 98.07% to $360000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $360000.0 in Q3 2025, $35.8 million in Q2 2025, and $279000.0 in Q1 2025.